Senti Biosciences, Inc.

Contributing Author

Recent Articles by Senti Biosciences, Inc.

Feb-11	Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) SNTI GlobeNewswire
Feb-03	Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026 SNTI GlobeNewswire
Jan-14	Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company's Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation SNTI GlobeNewswire
Jan-09	Senti Bio to Participate in Panel Presentation at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference SNTI GlobeNewswire
Dec-18	Senti Biosciences Announces New Employment Inducement Grants SNTI GlobeNewswire
Dec-09	Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia SNTI -35.56% GlobeNewswire
Dec-09	Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile SNTI -35.56% GlobeNewswire
Dec-04	Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Society of Hematology (ASH) Annual Meeting 2025 on Tuesday, December 9th at 8:00 AM ET SNTI GlobeNewswire
Nov-13	Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in December SNTI -10.06% SNTI -5.29% GlobeNewswire
Nov-03	Senti Bio to Present Updated Clinical Results of First-in-Class Logic Gated CD33/FLT3 Cell Therapy, SENTI-202, at the American Society of Hematology (ASH) Annual Meeting 2025 SNTI GlobeNewswire
Oct-16	Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference SNTI -5.63% GlobeNewswire
Oct-06	Senti Bio to Present at BioJapan SNTI GlobeNewswire
Sep-18	Senti Bio to Present at the MedInvest Biotech & Pharma Conference SNTI GlobeNewswire
Sep-02	Senti Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference SNTI GlobeNewswire
Aug-14	Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech SNTI GlobeNewswire
Aug-12	Senti Bio Participates in Virtual Investor "What This Means" Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia SNTI GlobeNewswire
Aug-07	Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025 SNTI -8.88% GlobeNewswire
Aug-05	Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia SNTI GlobeNewswire
Jul-22	Senti Biosciences Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference SNTI GlobeNewswire
Jul-21	Senti Bio's Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum SNTI GlobeNewswire
Jul-18	Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors SNTI GlobeNewswire
Jun-30	Senti Bio Participates in Nasdaq Amplify Spotlight Series SNTI GlobeNewswire
Jun-24	Senti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference SNTI GlobeNewswire
Jun-18	Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia SNTI -17.99% GlobeNewswire
Jun-09	Senti Biosciences Announces New Employment Inducement Grants SNTI -18.75% GlobeNewswire
Jun-06	Senti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLC SNTI +7.87% GlobeNewswire
May-22	Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar SNTI -5.28% GlobeNewswire
May-22	Senti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202 SNTI -5.28% GlobeNewswire
May-08	Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 SNTI GlobeNewswire
May-06	Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development SNTI GlobeNewswire
May-01	Senti Bio Releases Virtual Investor "What This Means" Segment SNTI GlobeNewswire
Apr-30	Senti Bio to Present at the Citizens JMP Life Sciences Conference SNTI GlobeNewswire
Apr-30	Senti Bio to Present at the Citizens JMP Life Sciences Conference SNTI GlobeNewswire

Senti Biosciences, Inc.

Recent Articles by Senti Biosciences, Inc.

Upgrade your FINVIZ experience